FDA Investigator Christopher D Washington
Christopher D Washington has conducted inspections on 11 sites in 1 countries as of 12 Mar 2018. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
11
Last Inspection Date:
12 Mar 2018
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Christopher D Washington:
Amalia C Himaya,
Angela Shepas,
Binh T Nguyen,
Bryan A Galvez,
Carrie A Hughes,
Caryn M Mcnab,
Cassandra L Abellard,
Cathleen A Carr Sharpe,
Cecilia H Kieu,
Christopher M Jenner,
Claudia Mperez Kasmarski,
Darren S Brown,
Darrin E Davis,
Deborah A Greco,
Diane Cvan Leeuwen,
Dogbeda F Mackenzie,
Donna Ltartaglino Besone,
Francisco,
Greg K Keshishyan,
Gunneet Kaur,
Henry E Carrillo,
Herminio C Francisco,
James R Fleckenstein,
Janet Pulver,
Jeffrey P Raimondi,
Jennifer M Gogley,
Joey V Quitania,
Judy C Nepsa,
Kari M Johansen,
Kelley,
Kelvin X Sanders,
Kham Phommachanh,
Lanita F Kelley,
Leonard H Lavi,
Liming Zhang,
Linda Thai,
Matthew R Clabeaux,
Maxyne T Lam,
Michael D Garcia,
Mihaly S Ligmond,
Natalie J Ayoub,
Nianna C Burns,
Phillip J Sample,
Rabin N Ghoshal,
Rafael A Kaup,
Richard A Abate,
Richmond K Yip,
Rocio Guzman Velazquez,
Saied A Asbagh,
Sean P Desbrow,
Shannon B Ruelle,
Sonia R Peterson,
Stacie A Woods,
Stephanie A Slater, MS,
Sumit Sen,
Tara L Stockton,
Truong Xuan Nguyen (Andy),
Trushani T Desai,
Uttaniti Limchumroon (Tom),
Vashti E Bocker,
Vioela J Caze,
Virgilio F Pacio, CSO,
Yen Tso Kuo,
Yi Lin,
Yumi J Hiramine,
Yvonne T Lacour,
Zachary A Bogorad
Christopher D Washington's Documents
Publish Date | Document Type | Title |
---|---|---|
December, 2017 | FDA 483 Response | bB BIOCHEM LABORATORIES INC. - Form 483R, 2018-01-09 |
June, 2017 | FDA 483 Response | Diasol Inc. - Form 483R, 2017-07-05 |
June, 2017 | FDA 483 | Diasol Inc. - Form 483, 2017-06-21 |
December, 2017 | FDA 483 | bB BIOCHEM LABORATORIES INC. - Form 483, 2017-12-18 |
October, 2017 | FDA 483 | Nexgen Pharma, Inc. - Form 483, 2017-10-20 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more